Insider Trading Insights: Penny Stocks Investors Should Watch Insider Trading Insights: Penny Stocks Investors Should Watch

Written By Michael Gary Scott



The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.


Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Insider Trading at Great Elm Group

  • The Trade: Great Elm Group, Inc. GEG 10% owner Imperial Capital Group Holdings II, LLC acquired a total of 124,090 shares at an average price of $1.96. The purchase amounted to approximately $238,539.
  • What’s Happening: On Feb. 13, Great Elm Group posted a loss for the second quarter.
  • What Great Elm Group Does: Great Elm Group Inc operates as a holding company, focusing on growing a scalable and diversified portfolio of long-duration, permanent capital vehicles.

Insider Trading at Earth Science Tech

  • The Trade: Earth Science Tech, Inc. ETST CEO Giorgio R. Saumat acquired a total of 15,000 shares at an average price of $0.08. The acquisition cost around $1,199.
  • What’s Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.
  • What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company with a current focus on emerging prospects in the health and wellness industry.

Insider Trading at Emmaus Life Sciences

  • The Trade: Emmaus Life Sciences, Inc. EMMA Co-President and COO Willis C Lee acquired a total of 115,200 shares at an average price of $0.13. The insider spent around $14,694 to buy those shares.
  • What’s Happening: On Feb. 2, Emmaus Life Sciences received marketing authorization for Puerto Rico.
  • What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases.
See also  Analysis of Netflix Stock Holding in Latest 13F Filings Unveiling Hedge Fund Holdings of Netflix

Don’t forget to check out our premarket coverage here